Analysis
Abbott identified the implementation of U.S. tariffs — introduced in April 2025 as part of the "Liberation Day" initiative — as a significant headwind to its gross margin and overall cost structure. Management estimated the net impact of these tariffs for fiscal year 2025 to be approximately $200M, primarily driven by increased costs on imported components and finished goods. Despite these costs, the company maintained its guidance for double-digit adjusted EPS growth by leveraging its diversified business model and operational efficiencies.
The company anticipates a "full-year effect" of these tariffs in fiscal year 2026, which represents a larger absolute headwind compared to the partial-year impact observed in 2025. To counteract these sustained costs, Abbott chartered a dedicated team focused on tariff mitigation strategies, which include supply chain adjustments, manufacturing relocations, and gross margin expansion initiatives. Management noted that once tariffs are established, they are difficult to reverse, necessitating long-term structural changes rather than temporary workarounds.
As a strategic long-term response, Abbott announced plans to construct a new cardiovascular manufacturing facility within the United States. This move is designed to reduce the company's reliance on imported products and mitigate the long-term impact of trade barriers on its medical device portfolio. While the tariffs created immediate margin pressure, Abbott's ability to achieve record gross margins in certain quarters of 2025 suggests that its broader productivity and pricing programs are effectively offsetting these regulatory headwinds.
Data
($M)
| Estimated Headwind | FY25A | FY26E |
|---|---|---|
| Gross Tariff Cost | 200 | 200 – 300 |
Source: Company filings, Marvin Labs
Financial Impact
- Cost Impact (Historic): $200M
- Cost Impact (Forward-Looking): $200M–$300M
Sources
Tariffs are expected to have an impact of a little less than $200 million.
The first meaningful impact of tariffs that we're feeling in gross margin is in the third quarter.
We've been able to work hard this year to be able to mitigate the impacts of tariffs as they have a full-year effect next year.